Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
This ia a multicenter, Single-Arm, Open-Label Phase I Clinical Study Evaluating the Safety and Tolerability of Pelareorep Combined with Paclitaxel Injection and the Intracorporal Process of Pelareorep in Chinese Patients with Advanced or Metastatic Breast Cancer.
Advanced or Metastatic Breast Cancer
DRUG: Pelareorep
Number of participants with Dose Limiting Toxicities (DLTs), DLTs are defined as study drug-related toxicities graded using Common Terminology Criteria for Adverse events of the National Cancer Institute (NCI CTCAE) V5.0 occurring during DLT period (the first 4 weeks of AN0025 administration in combination with dCRT), 4 Weeks
Objective response rate (ORR), The rate of patients with complete response and partial response in all tumor evaluable patients, 24 months|Disease control rate (DCR), The rate of patients with complete response, partial response and stable disease in all tumor evaluable patients, 24 months|Progression-free survival (PFS), The duration from the date of 1st dose to imaging progression or death, which earlier, 24 months|Duration of response (DOR), The duration from the first PR/CR to progression, 24 months|Overall survival (OS), The duration from the date of 1st dose to death, 24 months
This study will enroll patients with advanced or metastatic breast cancer to assess the safety and tolerability of Pelareorep at 1.5×10\^10, 3.0×10\^10, 4.5×10\^10 (TCID50) combined with paclitaxel to fix the MTD or RP2D.